Abstract
Given the remarkable progress that has recently been obtained in animal studies, the clinical use of stem and progenitor cells to correct or replace defective cell populations may soon become a reality. In order to develop effective cell therapies, the location and distribution of these cells must be determined in a non-invasive manner. Magnetic resonance (MR) tracking of magnetically labeled cells following transplantation or transfusion may fulfill this requirement. Indeed, a series of recent studies indicate that MRI cell tracking has great potential for further evaluation and optimization of cell therapy. Due to its biocompatibility and strong effects on T2(*) relaxation, iron oxide nanoparticles appear to be the contrast agent of choice, and several methods now exist to shuttle sufficient amount of these compounds into cells. Most of the tracking work has been carried out in disease models of the central nervous system, but, recently, the infarcted heart has also received attention. With its excellent spatial resolution and the ability to track labeled cells over prolonged periods of time, MR monitoring of cell therapy is likely to become an important technique in the foreseeable future.
Keywords: mr contrast agent, iron oxide, stem cell, progenitor cell, myelin, neurodegeneration, myocardial infarction
Current Pharmaceutical Biotechnology
Title: Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents
Volume: 5 Issue: 6
Author(s): Jeff W. M. Bulte and Dara L. Kraitchman
Affiliation:
Keywords: mr contrast agent, iron oxide, stem cell, progenitor cell, myelin, neurodegeneration, myocardial infarction
Abstract: Given the remarkable progress that has recently been obtained in animal studies, the clinical use of stem and progenitor cells to correct or replace defective cell populations may soon become a reality. In order to develop effective cell therapies, the location and distribution of these cells must be determined in a non-invasive manner. Magnetic resonance (MR) tracking of magnetically labeled cells following transplantation or transfusion may fulfill this requirement. Indeed, a series of recent studies indicate that MRI cell tracking has great potential for further evaluation and optimization of cell therapy. Due to its biocompatibility and strong effects on T2(*) relaxation, iron oxide nanoparticles appear to be the contrast agent of choice, and several methods now exist to shuttle sufficient amount of these compounds into cells. Most of the tracking work has been carried out in disease models of the central nervous system, but, recently, the infarcted heart has also received attention. With its excellent spatial resolution and the ability to track labeled cells over prolonged periods of time, MR monitoring of cell therapy is likely to become an important technique in the foreseeable future.
Export Options
About this article
Cite this article as:
M. Bulte W. Jeff and Kraitchman L. Dara, Monitoring Cell Therapy Using Iron Oxide MR Contrast Agents, Current Pharmaceutical Biotechnology 2004; 5 (6) . https://dx.doi.org/10.2174/1389201043376526
DOI https://dx.doi.org/10.2174/1389201043376526 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiapoptotic Effect of Novel Compound from Herba leonuri-Leonurine (SCM-198): A Mechanism Through Inhibition of Mitochondria Dysfunction in H9c2 Cells
Current Pharmaceutical Biotechnology Targeting SUMOylation Cascade for Diabetes Management
Current Drug Targets Current Use of Cardiac Biomarkers in Various Heart Conditions
Endocrine, Metabolic & Immune Disorders - Drug Targets Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews Endoplasmic Reticulum Stress as a Novel Therapeutic Target in Heart Diseases
Cardiovascular & Hematological Disorders-Drug Targets Statins and Vulnerable Plaque
Current Pharmaceutical Design Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Current Drug Targets Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design Possible Therapeutic Targets in Cardiac Myocyte Apoptosis
Current Pharmaceutical Design Actions of Relaxin on Non-Reproductive Tissues
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Therapy Against Ischemic Injury
Current Pharmaceutical Design Ventricular Arrhythmias in Seniors with Heart Failure: Present Dilemmas and Therapeutic Considerations: A Systematic Review
Current Cardiology Reviews From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry The Role of Myocardial Collagen Network in Hypertensive Heart Disease
Current Hypertension Reviews Meet Our Editorial Board Member
Current Cardiology Reviews Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry MicroRNA-130a Regulation of Desmocollin 2 in a Novel Model of Arrhythmogenic Cardiomyopathy
MicroRNA